Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis.
Krisya Louie, Sameer Jauhar, Jose Rubio et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined relapse trajectories in schizophrenia following antipsychotic discontinuation, utilizing data from five randomized trials. It included 417 participants and identified two relapse trajectories: rapid and delayed onset. Rapid relapse was associated with higher baseline symptom severity, but the proportion of rapid relapses did not differ significantly between treatment continuation and discontinuation groups.
Key findings
- Two distinct relapse trajectories were identified: rapid and delayed onset.
- Rapid relapse was associated with significantly higher baseline PANSS scores (p<0.0010).
- The proportion of rapid relapses did not differ significantly between discontinuation and continuation groups in either LAI or oral trials.
Why it matters
Understanding relapse trajectories can help clinicians better manage treatment plans for patients with schizophrenia, particularly in assessing the risks associated with antipsychotic discontinuation and tailoring monitoring strategies based on individual symptom profiles.